Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return...
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2022-01-21
- Target Recruit Count
- 7
- Registration Number
- NCT02586675
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT02483767
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT02476786
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT02430480
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Micro RNAs to Predict Response to Androgen Deprivation Therapy
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 42
- Registration Number
- NCT02366494
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
Detect V / CHEVENDO (Chemo vs. Endo)
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Prof. Wolfgang Janni
- Target Recruit Count
- 271
- Registration Number
- NCT02344472
- Locations
- 🇩🇪
University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02333370
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT02313051
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 672
- Registration Number
- NCT02278120
- Locations
- 🇺🇸
Penn State University Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Danbury Hospital SC, Danbury, Connecticut, United States
🇺🇸University Of California Los Angeles Dept of Onc, Los Angeles, California, United States
Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea
- Conditions
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT02132390
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.